home · filing · 0001171843-21-006167
8-K filed August 26, 2021, 7:59 PM ET
ticker BCRX
CIK 0000882796
leadership
confidence high
sentiment neutral
materiality 0.35
BioCryst appoints former FDA CDER director Steven Galson to board of directors
BIOCRYST PHARMACEUTICALS INC
Board expanded from 9 to 10; Galson effective Sept 1, 2021, term ends at 2022 annual meeting.
Galson is former FDA CDER director, acting U.S. surgeon general, and ex-SVP R&D at Amgen.
Receives automatic grant of 60,000 stock options upon joining, plus 40,000 annually subject to tenure.
Appointed to Science Committee; compensation per company's director compensation policy.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-09-01
Filed August 26, 2021, 7:59 PM ET
elected Steven Galson, M.D. to fill the vacancy created by the enlargement of the Board, effective September 1, 2021
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Steven Galson was appointed as Director at BIOCRYST PHARMACEUTICALS INC.
Action appointed
Role Director
Exact text from the filing
elected Steven Galson, M.D. to fill the vacancy created by the enlargement of the Board, effective September 1, 2021
View on SEC.gov
Source: SEC EDGAR
accession 0001171843-21-006167
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.